Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience

Christensen, Britt; Goeppinger, Sarah R.; Colman, Ruben J.; Siddiqui, Dania; Yarur, Andrés; Bochenek, Ashley A.; Wichmann, Alana; Hirsch, Ayal; Kinnucan, Jami; Sakuraba, Atsushi; Cohen, Russell D.; Rubin, David T.

doi:10.1016/s0016-5085(15)32937-1

Cited by 7 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding reflects current patterns of practice, particularly in CD, in which anti-TNF agents are generally used as first-line biological agents unless contraindications such as infective or malignant concerns exist. Indeed, the rate of prior anti-TNF exposure was as high as 87% in the Chicago cohort19 and higher still in the cohort recently reported by GETAID (Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif), with 99% of CD and 98% of patients with UC having previous exposure 20. These findings serve to demonstrate the refractory nature of the patients encountered at tertiary IBD referral centres.…”

Section: Discussionmentioning

confidence: 72%

“…Treatment outcomes were predefined as follows: clinical response was defined as a reduction of three or more in HBI or SCCAI, clinical remission was defined as HBI <5 or SCCAI <3. These definitions were based on their previously demonstrated (partial) validity25 26 and published post-marketing experiences of vedolizumab in an attempt to aid comparability of results 17 19…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Samaan

Pavlidis

Johnston

et al. 2016

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Methodsmentioning

confidence: 99%

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Samaan

Pavlidis

Johnston

et al. 2016

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

“…A group from Chicago, IL, USA reported monocentric clinical effectiveness data for 42 CD and 27 UC patients. 37 Here 38.5% of their CD and 40% of their UC patients achieved clinical remission in week 14. They identified colon involvement and bio-na€ ıve patients as predictors for vedolizumab response.…”

Section: Discussionmentioning

confidence: 93%

“…None of their patients had achieved clinical remission by then, but Harvey–Bradshaw index and partial Mayo scores dropped significantly ( P < 0.01 vs. 0.05, respectively). A group from Chicago, IL, USA reported monocentric clinical effectiveness data for 42 CD and 27 UC patients . Here 38.5% of their CD and 40% of their UC patients achieved clinical remission in week 14.…”

Section: Discussionmentioning

confidence: 99%

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study

Baumgart

Bokemeyer

Drabik³

et al. 2016

Aliment Pharmacol Ther

165

141

View full text Add to dashboard Cite

show abstract

“…5 ; Figure S2) [ 34 , 40 , 60 , 69 ]. Of 46 studies reporting safety outcomes, most were for UC/CD combined, rather than by separate indication (Table S4) [ 13 , 18 , 20 , 24 , 26 , 27 , 31 , 32 , 37 , 38 , 40 – 42 , 44 – 46 , 53 , 55 , 56 , 58 , 59 , 61 , 64 – 68 , 70 – 74 , 78 – 80 , 84 , 89 , 91 – 95 , 97 , 98 , 102 , 104 – 109 ].…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

et al. 2018

View full text Add to dashboard Cite

BackgroundSelective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.MethodsA systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn’s disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases were searched for real-world studies of vedolizumab in adult patients with UC/CD reporting clinical response, remission, corticosteroid-free remission, UC/CD-related surgery or hospitalization, mucosal healing, or safety published from May 1, 2014–June 22, 2017. Response and remission rates were combined in random-effects meta-analyses.ResultsAt treatment week 14, 32% of UC patients [95% confidence interval (CI) 27–39%] and 30% of CD patients (95% CI 25–34%) were in remission; and at month 12, 46% for UC (95% CI 37–56%) and 30% for CD (95% CI 20–42%). For UC, the rates of corticosteroid-free remission were 26% at week 14 (95% CI 20–34%) and 42% at month 12 (95% CI 31–53%); for CD they were 25% at week 14 (95%, CI 20–31%) and 31% at month 12 (95%, CI 20–45%). At month 12, 33–77% of UC and 6–63% of CD patients had mucosal healing. Nine percent of patients reported serious adverse events.ConclusionsVedolizumab demonstrated real-world effectiveness in patients with moderate-to-severely active UC or CD, with approximately one-half and one-third of patients, respectively, in remission at treatment month 12. These findings are consistent with clinical trial data and support the long-term benefit–risk profile of vedolizumab.Electronic supplementary materialThe online version of this article (10.1007/s00535-018-1480-0) contains supplementary material, which is available to authorized users.

show abstract

Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience

Cited by 7 publications

References 0 publications

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

Contact Info

Product

Resources

About